SHShahrier Hossain

Shahrier Hossain

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shahrier Hossain has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Dynamic biomarkers of kidney function in patients with newly diagnosed multiple myeloma receiving daratumumab‐based combination therapy

    by Poy Theprungsirikul, Api Chewcharat, Ayumi Takakura, Shahrier Hossain, Ava Kim, Mia B. Rubman, Sophia L. Wells, Kiana M. Zargari, Robert S. Rider, Ji Hyun Lee, et al.

  • Open Access

    Elranatamab: A novel B-cell maturation T-cell engager

    by Shahrier Hossain, Giada Bianchi

    B-cell maturation antigen (BCMA) is a highly expressed transmembrane receptor on malignant plasma cells, mediating cell survival. These characteristics make it an attractive target for novel cellular and immunotherapies. Elranatamab is a bispecific antibody targeting BCMA on plasma cells and CD3 on T cells. This leads to immune cell activation and the release of granzymes and perforins, with attendant killing of target cells. Overactivation of the immune system can lead to cytokine release syndrome (CRS) and immune cell associated neurotoxicity syndrome (ICANS). Compared to similar agents, elranatamab has a favorable safety profile with robust efficacy. It is currently approved for relapsed/refractory multiple myeloma with clinical trials evaluating its use in combination and in earlier lines of therapy.

  • Open Access

    A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM)

    by Yuxin Liu, Ji Hyun Lee, Clifton C. Mo, Taya Jamal Salman, Shahrier Hossain, Shonali Midha, Omar Nadeem, Taylor Nicholson, Jessica Croteau, Natalie Kazierad, et al.

    Monoclonal antibodies (mAbs) and antibody - drug conjugates (ADCs) are among the backbones of treatment for relapsed/refractory multiple myeloma (RRMM). Beyond current standard-of-care regimens, the roles of mAbs/ADCs are evolving associated with advances in first-line therapy, emerging data on additional regimens, and developments with immunotherapies and other novel agents. We review mechanisms of action, efficacy, real-world effectiveness, and key aspects of the safety profiles of daratumumab, isatuximab, elotuzumab, and belantamab mafodotin in RRMM. We consider efficacy in patient subgroups and the challenges of treatment sequencing and highlight new antigen targets and mAb/ADC therapies under investigation. We searched the published literature with PubMed and congress abstracts using drug names or classes and 'myeloma.' The widespread use of daratumumab and isatuximab in first-line therapy and evolving roles of CAR T-cell therapies and bispecific antibodies are reshaping RRMM treatment. mAb/ADC-based regimens remain key options in this setting, offering practical, effective, and tolerable approaches for real-world practice. Ongoing research will inform individualized treatment choices and rational sequencing of therapies, with a need for immune-based biomarkers and biologic profiling to enable optimal, integrated use of mAbs, ADCs, CAR T-cell therapies, and bispecific antibodies to further improve outcomes for patients with RRMM.


  • The impact of growth factor utilization on infection risk in patients receiving bispecific monoclonal antibodies

    by Yong Jun Bae, Houry Leblebjian, Robert Redd, Victoria Yeung, Shahrier Hossain

    Background: Bispecific monoclonal antibodies (BsAbs) are utilized in patients with relapsed or refractory multiple myeloma (MM) and light chain amyloidosis (AL amyloidosis) but are associated with high rates of neutropenia and infection. Granulocyte colony stimulating factors (G-CSF) offer a potential means to mitigate infection risk and maintain BsAb treatment, however their use alongside BsAbs is not well defined. Methods: This single-center, retrospective chart review included adult patients with MM or AL amyloidosis who received teclistamab, talquetamab, or elranatamab at Dana-Farber Cancer Institute from 2022 to 2025. The primary outcome was to assess the rate of infections in patients with or without concomitant G-CSF therapy. The secondary outcomes were to compare the infection characteristics and relative dose intensities of BsAbs in patients with or without concomitant G-CSF therapy and to describe the efficacy of G-CSF therapy. Results: Infection rates were comparable in patients that received G-CSF (60% with G-CSF vs. 41% without; p=0.055). Relative BsAb dose intensity was similar in patients that received G-CSF (95.2% with G-CSF vs. 100% without; p=0.23). G-CSF was effective in resolving grade 3 (89%) and grade 4 (75%) neutropenia, with a median time to resolution of 7 days, and same day administration with BsAb occurred in 69% of patients. Conclusions: G-CSF administration resulted in comparable infection rates and treatment intensity relative to those not receiving G-CSF. G-CSF was effective in resolving neutropenia, often permitting same-day BsAb administration. These findings support the feasibility and utility of G-CSF during BsAb therapy to minimize infection-related complications and treatment deviations


  • Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis

    by Pedro Vianna, Rajshekhar Chakraborty, Shahrier Hossain, Divaya Bhutani, Shannon Miller, Annemarie Rossi, Sarah A. M. Cuddy, Rodney H. Falk, Suzanne Lentzsch, Jacob P. Laubach, et al.

    Immunoglobulin light-chain (AL) amyloidosis is a plasma cell disorder characterized by progressive organ dysfunction secondary to deposition of organized immunoglobulin light-chain aggregates. Achievement of rapid and deep normalization of involved immunoglobulin free light chains is necessary to maximize chances of reversibility of organ dysfunction, which, in turn, results in improved quality and length of life. There are no US Food and Drug Administration (FDA)–approved therapies for patients with relapsed AL amyloidosis. B-cell maturation antigen–targeting (BCMA)-bispecific T-cell engagers teclistamab and elranatamab have shown high activity and acceptable safety profile in patients with relapsed and/or refractory multiple myeloma, leading to their FDA approval. Herein, we report on safety and efficacy of elranatamab for patients with relapsed and/or refractory AL amyloidosis. We treated 9 consecutive patients with advanced-stage AL amyloidosis with single-agent elranatamab, observing a 100% overall response and 67% complete response rate, including minimal residual disease negativity, with expected toxicities. Median time to hematological response was 9 days (range, 6-24), with deep suppression in involved free light chains observed within 1 cycle of therapy, translating in cardiac and renal responses at 3 to 6 months. These data support prospective studies exploring elranatamab for patients with relapsed AL amyloidosis.


  • Open Access

    Outcomes of Melflufen Treatment in Patients With Relapsed/Refractory Multiple Myeloma

    by Shahrier Hossain, Clifton Mo, Sarah Patches, Houry Leblebjian, Kathryn Goodrich, Eileen Regan, Kathleen O'NEill, Kim Noonan, Paul G. Richardson, Jacob Laubach

    Objective: Melphalan flufenamide (melflufen) plus dexamethasone is fully approved in Europe for patients with relapsed/refractory multiple myeloma (RRMM) with ≥ 3 prior lines of therapy. We analyzed the efficacy and safety of melflufen in the real‐world setting.Methods: In this retrospective analysis, we examined baseline features, efficacy, and safety outcomes with melflufen plus dexamethasone in a cohort of 12 patients with heavily pre‐treated RRMM at the Dana‐Farber Cancer Institute, USA.Results: Patients had received a median of 5.5 prior lines of therapy. Three patients (25%) had extramedullary disease, three (25%) cytogenetically high‐risk features, and five (42%) had received prior autologous stem cell transplantation. The overall response rate was 55% (complete response: three [27%], very good partial response: one [9%], partial response: two [18%] patients). Five patients (42%) had stable disease; one was non‐evaluable. Adverse events (AEs) were mostly hematologic and proved manageable; two patients had Grade 2 infections. Reasons for melflufen discontinuation were progressive disease (42%), drug withdrawal from the United States market (33%), AEs (17%), and sudden death (8%) unrelated to treatment.Conclusions: Consistent with clinical trial data, melflufen had an expected safety profile with manageable toxicity and clinically meaningful efficacy in patients with RRMM treated in the real‐world setting.